ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Core Viewpoint - ACELYRIN, INC. has received an unsolicited acquisition offer from Concentra Biosciences at $3.00 per share, alongside a contingent value right for 80% of net proceeds from any out-licensing or disposition of its development programs or intellectual property [1] Group 1: Acquisition Offer - Concentra Biosciences, controlled by Tang Capital Partners, has expressed interest in acquiring all outstanding shares of ACELYRIN for $3.00 per share in cash [1] - The offer includes a contingent value right that entitles shareholders to 80% of net proceeds from any future out-licensing or sale of ACELYRIN's development programs or intellectual property [1] Group 2: Merger Agreement - On February 6, 2025, ACELYRIN announced a merger agreement with Alumis Inc. in an all-stock transaction, expected to close in Q2 2025, pending stockholder approval and other customary conditions [2] - The ACELYRIN Board of Directors is committed to acting in the best interests of all stockholders and fulfilling its obligations under the merger agreement with Alumis [3] Group 3: Company Overview - ACELYRIN, INC. focuses on developing transformative medicines in immunology, with its lead program, lonigutamab, targeting IGF-1R for the treatment of thyroid eye disease [4]